Creating vaccines and driving value through partnerships and …
Novavax is a global biotechnology company with a proven vaccine technology, focused on developing our R&D assets and establishing partnerships to help protect health.
Who we are - Novavax
Novavax is a global biotechnology company with a proven vaccine technology. We are focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health.
Novavax's Updated Protein-based COVID-19 Vaccine Now an …
Nov 28, 2023 · Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been...
Novavax Investor Relations | Novavax
Novavax is a global biotechnology company with a proven vaccine technology, focused on developing our R&D assets and establishing partnerships to help protect health. View our earnings and investor presentations, latest press releases and events.
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and …
Sep 12, 2023 · Novavax expects doses will be available in thousands of locations across the U.S. in the coming days, including CVS Pharmacy and Rite Aid; Find Novavax's vaccine at us.novavaxcovidvaccine.com or vaccines.gov
Novavax Update: Where to Find Our COVID-19 Vaccine
Oct 7, 2024 · Novavax is committed to providing the most updated and comprehensive information about the locations where you can get access to the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705).
Novavax Reports First Quarter 2024 Financial Results and …
May 11, 2024 · GAITHERSBURG, Md., May 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for …
Novavax Initiates Phase 3 Trial for COVID-19-Influenza …
Dec 10, 2024 · The randomized Phase 3 trial builds on positive Phase 2 data and aims to further evaluate the immunogenicity and safety of a combination of Novavax's updated 2024-2025 COVID-19 vaccine, trivalent nanoparticle stand-alone seasonal influenza vaccine candidate and patented saponin-based Matrix-M adjuvant relative to separate administrations of ...
Press releases & statements | Novavax Investor Relations
Dec 4, 2024 · Novavax is a global biotechnology company with a proven vaccine technology. We are focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health.
Press Center - Novavax
Dec 10, 2024 · Novavax, Inc. (Nasdaq: NVAX) is a global biotechnology company focused on using our proven vaccine technology to help protect health through the development of our R&D assets and establishing partnerships